Kamunting Street Capital Management’s Ginkgo Bioworks DNA Stock Holding History

Kamunting Street Capital Management’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,500	Closed	-$169K	–	39
2022 Q4	$169K	Buy	+2,500	New	+$230K	0.27%	23
2022 Q3	–	Sell	-12,880	Closed	-$1.23M	–	38
2022 Q2	$1.23M	Buy	12,880 +2,880	+29%	+$351K	1.66%	12
2022 Q1	$1.61M	Buy	+10,000	New	+$1.95M	2.01%	13
2021 Q4	–	Sell	-24,967	Closed	-$11.6M	–	53
2021 Q3	$11.6M	Buy	+24,967	New	+$12.2M	5.17%	6

Other funds holding DNA

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACG

Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Kamunting Street Capital Management's DNA Position: Q1 2023 in Review

Kamunting Street Capital Management sold out of Ginkgo Bioworks (DNA) in Q1 2023, closing a stake of 2,500 shares — an estimated $169K sold.

Kamunting Street Capital Management first reported a position in DNA in Q3 2021 and held it in 4 quarters. The position peaked at $11.6M in Q3 2021. 313 funds tracked by Wall St. Rank hold DNA as of Q1 2023.

Kamunting Street Capital Management reported no remaining Ginkgo Bioworks position as of Q1 2023 after selling out during the quarter.
Kamunting Street Capital Management sold 2,500 Ginkgo Bioworks shares in Q1 2023, an estimated $169K.
Kamunting Street Capital Management first reported a position in Ginkgo Bioworks in Q3 2021 and held it in 4 quarters.
Kamunting Street Capital Management's Ginkgo Bioworks position peaked at $11.6M in Q3 2021.
313 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2023.

Based on Kamunting Street Capital Management's 13F filing for Q1 2023, filed 15 May 2023.